Kiora Pharmaceuticals Inc Dossier
Qualitative Analysis
Business overview
Kiora Pharmaceuticals, Inc. (NASDAQ: KPRX) is a clinical-stage specialty biopharmaceutical company dedicated to developing and commercializing advanced therapies for orphan retinal diseases that cause blindness. The company's strategic focus centers on targeting critical pathways underlying vision loss using innovative small molecules and molecular photoswitches. Kiora's lead pipeline asset is KIO-301, a first-in-class molecular photoswitch designed to restore light perception and functional vision in patients with late-stage inherited retinal degenerations, such as retinitis pigmentosa, choroideremia, and Stargardt disease, regardless of the underlying gene mutation. Additionally, the company is developing KIO-104, a next-generation, non-steroidal, immuno-modulatory small-molecule inhibitor of dihydroorotate dehydrogenase (DHODH) formulated for intravitreal delivery to treat retinal inflammatory diseases, including posterior non-infectious uveitis.
Research as of 20 Jun 2026
Strategic Initiatives
Growth programs, investments, and their expected impact
Advancing the clinical development of KIO-301 (Phase 2 ABACUS-2 trial) and KIO-104 (Phase 2 KLARITY trial) to establish clinical proof-of-concept.
Expected impact: Establish clinical proof-of-concept for lead assets to drive long-term commercialization and licensing opportunities.
Exploring the therapeutic potential of the KIO-300 ion-channel modulator platform beyond ophthalmic indications, including preclinical evaluations in oncology and epilepsy.
Expected impact: Broaden the company's pipeline and addressable market into non-ophthalmic orphan indications.
Mergers, Acquisitions & Partnerships
Recent deals and strategic collaborations
Strategic Partnerships
Provides substantial non-dilutive funding and a global commercial partner for KIO-301.
Terms: $16 million upfront payment received in 2024, up to $285 million in additional development, regulatory, and commercial milestones, plus tiered royalties of up to the low 20% range on net sales.
Extends the global commercial reach of KIO-301 into key Asian marketplaces, including Japan and China.
Terms: $1.25 million non-dilutive upfront option fee received in 2025. If exercised, Kiora is eligible for an additional mid-single digit million upfront payment, up to $109.5 million in milestone payments, and tiered mid-double-digit royalties on net sales.